Mehrdad Bakhtiary - Cellular & Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mohsen Marzban - Cellular & Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mehdi Mehdizadeh - Cellular & Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Taghi Joghataei - Cellular & Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran
Samideh Khoei - Cellular & Molecular Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mahdi Tondar - Department of Anatomy, Tehran University of Medical Science, Tehran, Iran
Vahid Pirhajati Mahabadi - Department of Anatomy, Tehran University of Medical Science, Tehran, Iran
Bahareh Laribi - Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran
Asghar Ebrahimi - Department of Biotechnology and Bioscience, Milano-Bicocca University, Milan, Italy
Seyed Jafar Hashemian - Department of Anatomy, Tehran University of Medical Science, Tehran, Iran
Navid Modiry - Department of Anatomy, Tehran University of Medical Science, Tehran, Iran
Soraya Mehrabi - Department of physiology, Tehran University of Medical Sciences, Tehran, Iran

Objective(s) Clinical studies of treating traumatic brain injury (TBI) with autologous adult stem cells led us to examine the impression of a combination therapy. This was performed by intravenous injection of human umbilical cord matrix stem cell (hUCMSC-Wharton,s jelly stem cell) with bone marrow cell mobilized by granulocytecolony stimulating factor (G-CSF) in rats injured with cortical compact device. Materials and Methods Adult male Wistar rats (n= ۵۰) were injured with controlled cortical impact device and divided into five groups. All injections were performed ۱ day after injury into the tail veins of rats. Neurological functional evaluation of animals was performed before and after injury using modified neurological severity scores (mNSS). Animals were sacrificed ۴۲ days after TBI and brain sections were stained by Brdu immunohistochemistry. Results Statistically significant improvement in functional outcome was observed in treatment groups when compared with control (P< ۰.۰۱). mNSS showed no significant differences among the hUCMSC and G-CSF treated groups at any time point (end of trial). Rats with hUCMSC + G-CSF treatment had a significant improvement on mNSS at ۵ and ۶ week compared to other treatment group (P< ۰.۰۱). Conclusion Histological analysis in G-CSF+ hUCMSC treated traumatic rats exhibited significant increase in numbers of Brdu immunoreactive cells in their traumatic core compared with other labeled group.

Combine Therapy, G-CSF, Stem cell, TBI, Whartons jelly